Erschienen in:
Open Access
01.12.2020 | Correction
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
verfasst von:
Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Marangoni, Lesley-Ann Martin
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2020
Correction to: Breast Cancer Research (2019) 21:135
https://doi.org/10.1186/s13058-019-1222-0
After publication of the original article [
1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.